Ignacio J. Molina

Ignacio J. Molina

Auto-generated profile, based on publicly available information

Ignacio J. Molina

Institute of Biopathology and Regenerative Medicine, Center for Biomedical Research. Health Sciences Technology Park, University of Granada, Granada, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2010 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
CRCarmen Ruiz-Ruiz
Carmen Ruiz-Ruiz
Girish Kumar SRIVASTAVAGirish Kumar SRIVASTAVA
Girish Kumar SRIVASTAVA
DCDiana Carranza
Diana Carranza
JMJuan A. Mata
Juan A. Mata
Inmaculada LlamasInmaculada Llamas
Inmaculada Llamas
IMIgnacio J. Molina
Ignacio J. Molina

25 November 2010 in Gene Therapy
Verified
Journal Article
Closed access
ZRZ Romero
Z Romero
STS Torres
S Torres
MCM Cobo
M Cobo
PMP Muñoz
P Muñoz
JUJ D Unciti
J D Unciti
IMI J Molina
I J Molina

25 March 2015 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
MVMaría Pineda de las Infantas y Villatoro
María Pineda de las Infantas y Villatoro
STSara Torres-Rusillo
Sara Torres-Rusillo
JUJuan Diego Unciti-Broceta
Juan Diego Unciti-Broceta
PFPablo Fernandez-Rubio
Pablo Fernandez-Rubio
MLMaria Angelica Luque-Gonzalez
Maria Angelica Luque-Gonzalez
JDJuan Díaz-mochon
Juan Díaz-mochon
A 18-member library of 6,8,9-poly-substituted purines was prepared from pyrimidines, primary alcohols, and N,N-dimethylamides under basic conditions via a novel one-pot synthetic pathway controlled by amide sizes and the novel analogues were tested against two leukemia cell lines: Jurkat (acute T cell leukemia) and K562 (chronic erythroleukemia) cells. Compounds having a benzoxy group at C6 position of the aromatic ring exhibited antiproliferative activity in Jurkat cells whereas all compounds induced a lower effect on K562 cells. Analysis of cell cycle, Annexin-V staining, and cleavage of initiator caspases assays showed that the active purine analogues induce cell death by apoptosis. Based on these results, a new purine derivative was synthesized, 6-benzyloxy-9-tert-butyl-8-phenyl-9H-purine (6d), which displayed the highest activity of the series against Jurkat cell lines. Finally, 33P-radiolabeled kinase assays using 96 recombinant human kinases known to be involved in apoptotic events were performed. Just one of the kinases tested, DAPK-1, was inhibited 50% or more by the phenotypic hits at 10 μM, suggesting that the inhibition of this target could be responsible for the induction of cell death by apoptosis. In agreement with the phenotypic results, the most active antiproliferative agent, 6d, displayed also the lowest IC50 value against recombinant DAPK1 (2.5 μM), further supporting the potential role of this protein on the observed functional response. DAPK-1 inhibition led by 6d together with its pro-apoptotic properties against the Jurkat line makes it an interesting candidate to further investigate the role of DAPK1 kinase in triggering apoptosis in cancer cells, a role which is attracting recent interest.

1 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Nieves MartínezNieves Martínez
Nieves Martínez
ALAlvaro Lorente-Macias
Alvaro Lorente-Macias
AGAlejandro García-Salguero
Alejandro García-Salguero
NCNuria Cortes-Serra
Nuria Cortes-Serra
ÁFÁngel Fenollar-Collado
Ángel Fenollar-Collado
JPJulio Alonso Padilla
Julio Alonso Padilla
Malaria and Chagas disease, caused by Plasmodium spp. and Trypanosoma cruzi parasites, remain important global health problems. Available treatments for those diseases present several limitations, such as lack of efficacy, toxic side effects, and drug resistance. Thus, new drugs are urgently needed. The discovery of new drugs may be benefited by considering the significant biological differences between hosts and parasites. One of the most striking differences is found in the purine metabolism, because most of the parasites are incapable of de novo purine biosynthesis. Herein, we have analyzed the in vitro anti-P. falciparum and anti-T. cruzi activity of a collection of 81 purine derivatives and pyrimidine analogs. We firstly used a primary screening at three fixed concentrations (100, 10, and 1 µM) and progressed those compounds that kept the growth of the parasites < 30% at 100 µM to dose–response assays. Then, we performed two different cytotoxicity assays on Vero cells and human HepG2 cells. Finally, compounds specifically active against T. cruzi were tested against intracellular amastigote forms. Purines 33 (IC50 = 19.19 µM) and 76 (IC50 = 18.27 µM) were the most potent against P. falciparum. On the other hand, 6D (IC50 = 3.78 µM) and 34 (IC50 = 4.24 µM) were identified as hit purines against T. cruzi amastigotes. Moreover, an in silico docking study revealed that P. falciparum and T. cruzi hypoxanthine guanine phosphoribosyltransferase enzymes could be the potential targets of those compounds. Our study identified two novel, purine-based chemotypes that could be further optimized to generate potent and diversified anti-parasitic drugs against both parasites.

23 September 2016 in NeuroMolecular Medicine
Verified
Journal Article
Closed access
PDF file
DCDiana Carranza
Diana Carranza
AVAna Karina Vega
Ana Karina Vega
STSara Torres-Rusillo
Sara Torres-Rusillo
EMEnrique Montero
Enrique Montero
Luis Javier Martinez-GonzalezLuis Javier Martinez-Gonzalez
Luis Javier Martinez-Gonzalez
IMIgnacio J. Molina
Ignacio J. Molina

1 October 2015 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
PFPablo Fernández‐Rubio
Pablo Fernández‐Rubio
STSara Torres‐Rusillo
Sara Torres‐Rusillo
IMIgnacio J. Molina
Ignacio J. Molina